{"entity":{"id":"icp-248","kind":"drug","name":"ICP-248","aka":[],"tldr":"ICP-248 is an experimental small-molecule drug from Beijing InnoCare Pharma Tech in phase 3 trials for mantle cell lymphoma and chronic lymphocytic leukaemia, with its target not yet stated publicly.","summary":"ICP-248 is a small-molecule drug developed by Beijing InnoCare Pharma Tech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06378138 (ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (APEX-03)), in mantle cell lymphoma and chronic lymphocytic leukaemia. The largest, NCT06378138, plans to enrol 226 participants with primary completion expected 2030-11-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ICP-248","url":"https://clinicaltrials.gov/search?intr=ICP-248"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["innocare"],"institutions":[],"pathways":[],"terms":[],"trials":["apex-03","nct07082686"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/icp-248/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"company":[{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/"}],"trial":[{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/"},{"id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/"}]}}